A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in
subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated
form of exenatide, may be beneficial in PD and is being developed as a potential treatment
for neurodegenerative disorders.
For more information, please visit:
PrismPDstudy.com